Transcript Slide 1

Terms of Use
 The In the Clinic® slide sets are owned and copyrighted by the
American College of Physicians (ACP). All text, graphics,
trademarks, and other intellectual property incorporated into the
slide sets remain the sole and exclusive property of ACP. The slide
sets may be used only by the person who downloads or purchases
them and only for the purpose of presenting them during not-forprofit educational activities. Users may incorporate the entire slide
set or selected individual slides into their own teaching
presentations but may not alter the content of the slides in any way
or remove the ACP copyright notice. Users may make print copies
for use as hand-outs for the audience the user is personally
addressing but may not otherwise reproduce or distribute the slides
by any means or media, including but not limited to sending them as
e-mail attachments, posting them on Internet or Intranet sites,
publishing them in meeting proceedings, or making them available
for sale or distribution in any unauthorized form, without the
express written permission of the ACP. Unauthorized use of the In
the Clinic slide sets constitutes copyright infringement.
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
* For Best Viewing:
Open in Slide Show Mode
(Click on
in bottom right)
or
From the View menu, select
the Slide Show option
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
in the clinic
The Polycystic
Ovary Syndrome
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
Who is at risk for PCOS?
Factors that seem to increase risk
 Family history
 BMI >30 kg/m2
 >⅓ w/PCOS obese
 ≈⅓ have impaired glucose tolerance
 ≈20% w/ polycystic ovaries asymptomatic
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
What symptoms and signs should
prompt clinicians to consider PCOS?
 Hyperandrogenemia
 Hirsutism, acne, alopecia, acanthosis nigricans
 Menstrual irregularity
 Infertility
 Obesity (particularly abdominal)
 Other signs and symptoms: Hypertension, hyperlipidemia,
CVD; obstructive sleep apnea; depression
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
ESHRE/ASRM* criteria
 First: exclude other medical conditions that cause
irregular menstrual cycles and androgen excess
 Then: confirm ≥2 of following present:
 Oligoovulation or anovulation
 Elevated levels of circulating androgens or clinical
manifestations of androgen excess
 Polycystic ovaries on ultrasonography
 NOTE: Polycystic ovaries alone ≠ PCOS
 Most obese women w/oligomenorrhea have PCOS
*European Society for Human Reproduction and Embryology and American
Society for Reproductive Medicine
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
What is the typical menstruation pattern
in PCOS?
 Oligomenorrhea
 Typically ≥35 days between cycles
 Only 4 to 9 periods/year
 Occasionally, menstruation cycle more normal, but
menses very light
 Some w/PCOS do not menstruate at all
 Consider PCOS: if menstrual irregularity began at
menarche and continued >1 yr
 Consider other diagnoses: if menstrual irregularity
began years after puberty or suddenly worsened
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
How does PCOS affect fertility?
 ≈90% anovulation infertility PCOS-related
 No luteinizing hormone surge, so ovulation doesn’t occur
 Pregnancy can often be achieved
 With lifestyle modifications (weight loss), drug treatments,
or surgical approaches to infertility
 Infertility workup of both partners should precede drug
therapy for infertility
 Refer women w/PCOS and fertility concerns to specialist
PCOS increases risk for pregnancy complications
 Gestational diabetes, pregnancy-induced high BP
and preeclampsia, preterm labor
 Miscarriage (risk unclear)
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
Which lab tests are useful in diagnosis?
 Serum testosterone
 Free (bioavail) and total testosterone levels usually increased
 Androstenedione
 May have slightly better sensitivity in US-proven PCOS
 LH, FSH
 High normal LH & normal FSH with ratio >2 consistent with Dx
 Serum prolactin
 May be slightly elevated
 Dehydroepiandrosterone (DHEA)
 Often increased; if markedly so, consider adrenal neoplasia
 Fasting glucose level and glucose tolerance test
 Impaired glucose tolerance in ⅓ with PCOS
 Fasting cholesterol, triglycerides, HDL (for assessment of CV risk)
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
Is an imaging study documenting cystic
ovaries necessary for diagnosis?
 Yes, unless diagnosis already clear
 Polycystic ovary morphology on US: 1 of 3 criteria
 Imaging advances allow improved measurement
capabilities and resolution
 Criteria defining polycystic ovaries:
 ≥12 follicles in each ovary (2 to 9 mm diameter)
 Or increased ovarian volume (>10 cm3)
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
What other diagnosis should clinicians
consider?
 Late-onset congenital adrenal hyperplasia
 Androgen-producing neoplasms
 Cushing syndrome
 Hyperprolactinemia
 Pregnancy
 Hypothyroidism
Alternate causes of oligo/amenorrhea
Chronic illness, stress, excessive exercise
Eating disorder, poor nutrition, low weight
Thyroid dysfunction, estrogen-secreting &
pituitary tumor, illegal use of anabolic
steroids
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
CLINICAL BOTTOM LINE: Diagnosis...
 Consider PCOS: irregular menstruation, infertility, obesity,
and hyperandrogenemia
 Exclude other conditions causing similar symptoms
 If androgen levels very high: ? adrenal/ovarian neoplasia
 Make diagnosis: if ≥2 of following are present:
 Oligoovulation or anovulation
 Elevated levels of circulating androgens or clinical
manifestations of androgen excess
 Polycystic ovaries on ultrasonography
 Most important part of history: symptom onset
 If symptoms began years after puberty or have suddenly
worsened, other diagnoses more likely
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
What is the role of diet in the
management of patients with PCOS?
 Loss of abdominal fat helps restore ovulation
 Just 2%-5% decrease in total body weight improves
 Menstrual regularity and ovulatory function
 Hirsutism
 Insulin sensitivity
 Response to fertility medication
 Refer patients to dietician for dietary modifications
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
When is drug therapy appropriate, and
what are available options?
 Oral contraceptive
 Regularizes menstruation, reduces hyperandrogenism; improves
body composition and insulin sensitivity
 Spironolactone
 Improves hyperandrogenic manifestations
 Cyproterone acetate
 Potent antiandrogen agent; unavailable in U.S.
 Finasteride
 Potent antiandrogen agent
 Eflornithine
 Slows hair growth everywhere or just on face
 Metformin
 Improves ovulation & glucose tolerance; may reduce testosterone
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
When fertility is the primary concern,
what treatment options are available?
 Lifestyle modifications for weight loss
 Clomiphene citrate
 Estrogen-like hormone increases FSH and LH levels and
improves ovulation chances
 Clomiphene + metformin
 Benefit of adding insulin sensitizer uncertain
 Gonadotropins, if clomiphene-insensitive
 Improves fertility, but often results in follicle overproduction
 Laparoscopic ovarian surgery
 Doesn’t trigger ovarian hyperstimulation
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
What are treatment options for hirsutism?
 Local measures: shaving, waxing, lasers, electrolysis
 Topical eflornithine cream
 Retards hair growth
 Oral contraceptives
 May reduce hirsutism and acne
 Cyproterone (antiandrogen agent) + oral contraceptives
 Effective but reduces libido, causes liver function changes
 Insulin-sensitizing agents
 Not recommended for cosmetic purposes
 Best result: combine systemic + nonsystemic therapies
 Hirsutism slow to respond to therapy (≥6 months)
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
What are the risks for prolonged amenorrhea?
 Elevated estrogen levels cause endometrial proliferation
 Increases risk for endometrial carcinoma
 Disorders with PCOS that  endometrial carcinoma risk:
 Obesity
 Hyperinsulinemia
 Diabetes
 Anovulatory cycles
 High androgen levels
 >3 months amenorrhea: consider progesterone challenge
 ≥1 year amenorrhea In women with PCOS: ultrasound to
measure endometrial thickness and possible biopsy if
endometrium >14 mm
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
What interventions minimize the risks of
prolonged amenorrhea?
 Cyclic progestin
 Oral contraceptives with combo estrogen + progestin
 Insulin-sensitizing drugs
 Weight loss
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
How should clinicians manage follow-up
care for women with PCOS?
 Check menstrual pattern every 3-12 months
 If menses >3 mo apart, initiate Provera challenge and/or
oral contraceptive
 Check hyperandrogenic symptoms every 3-6 months
 Document acne severity and hirsutism, including topical
measures
 Ask about pregnancy plans as clinically appropriate
 Planning needed so patient not on contraindicated drugs in
pregnancy
 Measure weight, waist circumference, and blood
pressure regularly
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
Laboratory tests
 Order fasting glucose or 2-hr glucose tolerance test
annually
 Check fasting total cholesterol, triglyceride, and HDL
cholesterol levels every 1-3 years
 Order Liver function tests only if patient is receiving a
medication known to affect liver function
 Nondrug therapy
 Assess patient readiness to make changes in diet
and/or exercise as clinically appropriate
 Drug therapy
 Check for adverse events as clinically appropriate
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
Does pregnancy in women with PCOS
carry specific risks?
 Increased maternal risk for…
 Gestational diabetes
 Preeclampsia (possibly)
 Hyperstimulation syndrome (if gonadotropins used)
 Increased fetal risk for…
 Preterm birth
 Admission to neonatal ICU
 Reduce risk factors before conception
 Closer follow-up and more fetal monitoring needed
during pregnancy
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.
CLINICAL BOTTOM LINE: Treatment...
 Focus on treating symptoms
 If patient is overweight, encourage weight loss
 If patient is not seeking pregnancy: consider oral
contraceptives, sometimes combined with antiandrogen agent
 If patient is seeking pregnancy: clomiphene commonly used
 Insulin sensitizer (metformin) may also be beneficial
 If patient is pregnant: beware increased complication risk
 Women should report prolonged amenorrhea: so that a
progesterone challenge or endometrial biopsy can be done
© Copyright Annals of Internal Medicine, 2011
Ann Int Med. 154 (3): ITC2-1.